O'Brien Greene & Co’s Eli Lilly LLY Stock Holding History

O'Brien Greene & Co’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$828K	Hold	900	–	–	0.23%	60
2025 Q4	$967K	Hold	900	–	–	0.29%	53
2025 Q3	$687K	Sell	900 -79	-8%	-$58.8K	0.21%	68
2025 Q2	$763K	Sell	979 -3	-0.3%	-$2.33K	0.25%	63
2025 Q1	$811K	Sell	982 -1	-0.1%	-$832	0.27%	58
2024 Q4	$759K	Buy	983 +79	+9%	+$65.4K	0.25%	65
2024 Q3	$801K	Sell	904 -51	-5%	-$45.9K	0.25%	66
2024 Q2	$865K	Buy	955 +12	+1%	+$9.6K	0.27%	60
2024 Q1	$734K	Hold	943	–	–	0.24%	69
2023 Q4	$550K	Buy	943 +35	+4%	+$20.4K	0.19%	78
2023 Q3	$488K	Sell	908 -7	-0.8%	-$3.61K	0.18%	81
2023 Q2	$429K	Sell	915 -25	-3%	-$10.5K	0.15%	87
2023 Q1	$323K	Hold	940	–	–	0.12%	105
2022 Q4	$344K	Sell	940 -1,925	-67%	-$683K	0.13%	103
2022 Q3	$927K	Buy	2,865 +1,910	+200%	+$605K	0.12%	106
2022 Q2	$310K	Hold	955	–	–	0.12%	112
2022 Q1	$273K	Sell	955 -1	-0.1%	-$257	0.09%	120
2021 Q4	$264K	Buy	956 +56	+6%	+$14.2K	0.09%	123
2021 Q3	$208K	Hold	900	–	–	0.08%	128
2021 Q2	$207K	Buy	+900	New	+$181K	0.07%	131

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

O'Brien Greene & Co's LLY Position: Q1 2026 in Review

O'Brien Greene & Co held its Eli Lilly (LLY) position steady in Q1 2026 at 900 shares worth $828K. The position accounts for 0.23% of the portfolio, ranked #60.

O'Brien Greene & Co first reported a position in LLY in Q2 2021 and has held it in 20 quarters since. The position peaked at $967K in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

O'Brien Greene & Co held 900 shares of Eli Lilly worth $828K as of Q1 2026.
O'Brien Greene & Co left its Eli Lilly share count unchanged in Q1 2026.
Eli Lilly made up 0.23% of O'Brien Greene & Co's portfolio in Q1 2026, its #60 holding.
O'Brien Greene & Co first reported a position in Eli Lilly in Q2 2021 and has held it in 20 quarters since.
O'Brien Greene & Co's Eli Lilly position peaked at $967K in Q4 2025.
4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on O'Brien Greene & Co's 13F filing for Q1 2026, filed 6 May 2026.